|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||85.83 - 86.75|
|52-week range||69.53 - 86.90|
|PE ratio (TTM)||30.87|
|Forward dividend & yield||2.72 (3.17%)|
|1y target est||93.00|
Results from CLARITY study show Cosentyx® (secukinumab) was significantly more effective than Stelara®* (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks Data support findings from the CLEAR study, which found Cosentyx was superior to Stelara®* in achieving sustained skin clearance (PASI 90) at 52 weeks Cosentyx is the first and only fully human interleukin-17A (IL-17A) inhibitor that showed sustained skin clearance rates at 5 years in patients from a psoriasis Phase III study
Adalimumab is an anti-TNF medicine used to treat a range of immunological diseases The comprehensive data package provided is expected to demonstrate that Sandoz proposed biosimilar adalimumab matches the reference biologic medicine in terms of safety, efficacy and quality-
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? In December 2017, Teva Pharmaceutical Industries (TEVA) announced a restructuring plan to recuperate sales. Its stock has had a bull run since the announcement, rising 44.5% since the company’s weak earnings results for fiscal 3Q17 on November 2, 2017.
Novartis appoints experienced pharmaceuticals industry leader with strong marketing skills to drive oncology business further Novartis appoints ad interim leader for its Global Drug Development organization
Novartis (NVS) announced the initiation of a trial on the biosimilar version of Cosentyx which will compare the drug to its proposed biosimilar for the treatment of ankylosing spondylitis.
In 3Q17, Imbruvica reported global revenues close to $688 million for AbbVie (ABBV). This represented a YoY (year-over-year) growth of ~37.3%. The drug reported revenues of close to $574 million in the US, which represents a YoY rise a close to 31.0%.
The agreement granted Ignyta exclusive global rights to develop and commercialize entrectinib. Under the license, Ignyta’s development rights are exclusive for entrectinib for the term of the agreement. The license also grants exclusive rights to Ignyta for a term of five years with respect to any product candidate that NMS might develop that has activity against the target proteins of entrectinib.
AbbVie (ABBV) has projected Imbruvica’s annual revenues to reach $5 billion by 2020. The drug has already changed the treatment paradigm in the second line plus CLL segment and for CLL patients with 17p deletion. AbbVie expects that in the future, nearly eight out of ten CLL patients will benefit from an Imbruvica-based therapy at one point or another.
Delaware-based Ignyta (RXDX) is focused on precision medicine in oncology. It endeavors to eradicate residual disease or the source of a reoccurrence of cancer in targeted patient populations. Ignyta is pursuing an integrated therapeutic and diagnostic strategy to treat cancer patients.
As we discussed earlier, Incyte (INCY) reported revenue of $381.5 million in 3Q17, a 41.6% rise over its revenue of $269.5 million in 3Q16. This revenue growth was driven by increased demand for the drug Jakafi. The above graph shows a revenue breakup for Incyte over the last few quarters.
AbbVie (ABBV) is focused on expanding Risankizumab’s label for multiple indications such as psoriatic arthritis, ulcerative colitis, and Crohn’s disease. The company expects to witness a significant rise in demand for Crohn’s disease and ulcerative colitis patients, mainly driven by increasing diagnosis rates and the greater prevalence of patients already treated with biologics.
SURPASS is the first head-to-head superiority trial versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS) EXCEED is the first head-to-head superiority trial versus Humira®* in psoriatic arthritis (PsA) Cosentyx is a targeted biologic inhibiting IL-17A, cornerstone cytokine involved in the inflammation of entheses
In 3Q17, Novo Nordisk’s (NVO) NovoMix reported revenues of 2.4 billion Danish krone (or DKK), which reflected ~1% growth on year-over-year (or YoY) basis.
CAMBRIDGE, Mass., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced the initiation of a Phase 2b clinical study of AKCEA-APOCIII-LRx in patients with hypertriglyceridemia and established cardiovascular disease (CVD). ...